Radiomics Based on Dynamic Contrast-Enhanced MRI to Early Predict Pathologic Complete Response in Breast Cancer...

To investigate the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-based radiomics at baseline and after two cycles of neoadjuvant therapy (NAT) and associated longitudinal changes for early prediction of the NAT response in patients with breast cancer.

One hundred seventeen patients with breast cancer who underwent DCE-MRI before NAT and after two cycles of NAT from April 2019 to November 2021 were enrolled retrospectively. Patients were randomly divided into a training set (n = 81) and a test set (n = 36) at a ratio of 7:3. Clinical-pathological data and the relative tumor maximum diameter regression value (diameter%) were also collected. A total of 851 radiomic features were extracted from the phase with the most pronounced tumor enhancement on DCE-MRI T1 imaging acquired both pre- and post-treatment. Delta and delta% radiomics features were also calculated. The Least Absolute Shrinkage and Selection Operator (LASSO) method was applied to select features, and a logistic regression model was used to calculate pre-NAT, early-NAT, delta, and delta% radscores and then select among four radscores to build a Fusion radiomics model. The final clinical-radiomics model was constructed by combining fusion radscores and clinical-pathological variables. The discrimination and clinical utility of the models were further evaluated and compared.

The area under the curve (AUC) values of the fusion radiomics model based on pre-NAT, Delta, and Delta% radscores were 0.868 of 0.825. The clinical-radiomics model integrating Fusion radscores and clinical-pathological variables achieved AUC values of 0.920 of 0.884, which were higher than those of the clinical model constructed by AUC values (0.858/0.831), although no significant improvement was observed in the test set (Delong test, p = 0.196). Decision curve analysis (DCA) showed that the clinical-radiomics model demonstrated more clinical utility than the clinical model.

DCE-MRI-based radiomics features may have potential for pathological complete response (pCR) prediction in the early phase of NAT. By combining radiomics features and clinical-pathological characteristics, higher diagnostic performance can be achieved.